{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:39:17Z","timestamp":1793738357073,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.euo.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T23:36:08Z","timestamp":1725147368000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)"],"prefix":"10.1016","volume":"8","author":[{"given":"Roberto","family":"Contieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Y.C.","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.08.001_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2024.08.001_b0010","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)","author":"Gontero","year":"2024"},{"key":"10.1016\/j.euo.2024.08.001_b0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.euo.2024.08.001_b0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0035","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1464-410X.2008.07966.x","article-title":"Quality control in transurethral resection of bladder tumours","volume":"102","author":"Herr","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.08.001_b0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2018.10.027","article-title":"The perioperative morbidity of transurethral resection of bladder tumor: implications for quality improvement","volume":"125","author":"Pereira","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.08.001_b0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.urolonc.2009.07.020","article-title":"Bladder cancer in the elderly","volume":"27","author":"Shariat","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0050","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)30874-7","article-title":"Evolution and patterns of global health financing 1995\u20132014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries","volume":"389","author":"Dieleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.08.001_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004\u20132013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.08.001_b0060","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/cncr.32185","article-title":"The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non\u2013muscle-invasive bladder cancer","volume":"125","author":"Schroeck","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2024.08.001_b0065","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JU.0000000000003639","article-title":"International Bladder Cancer Group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance","volume":"210","author":"Tan","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2024.08.001_b0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0080","unstructured":"National Institute for Health and Care Excellence. 2019 surveillance of bladder cancer: diagnosis and management (NICE guideline NG2). London, UK: NICE; 2019. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551803\/."},{"key":"10.1016\/j.euo.2024.08.001_b0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bju.14995","article-title":"Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)","volume":"125","author":"Matulay","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.08.001_b0090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0095","article-title":"Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis","volume":"27","author":"Petrelli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.euo.2024.08.001_b0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MOU.0000000000001028","article-title":"Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?","volume":"32","author":"von Deimling","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0110","doi-asserted-by":"crossref","first-page":"165.e19","DOI":"10.1016\/j.urolonc.2015.11.005","article-title":"Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer","volume":"34","author":"Hern\u00e1ndez","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","article-title":"Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) experience","volume":"5","author":"Contieri","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0120","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.03.025","article-title":"When and how to perform active surveillance for low-risk non\u2013muscle-invasive bladder cancer","volume":"9","author":"Contieri","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.08.001_b0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","article-title":"Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project","volume":"199","author":"Hurle","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0210-4806(05)73298-8","article-title":"[Is it necessary to always treat the relapses of superficial bladder tumour at the moment of diagnosis? Preliminary communication]","volume":"29","author":"Mart\u00ednez C\u00e1ceres","year":"2005","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2024.08.001_b0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.juro.2007.08.171","article-title":"Conservative management of low risk superficial bladder tumors","volume":"179","author":"Pruthi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.acuro.2022.01.002","article-title":"Surveillance and office management of low-grade Ta bladder tumors","volume":"46","author":"Lokeshwar","year":"2022","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2024.08.001_b0145","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-5347(17)54246-9","article-title":"Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients","volume":"127","author":"Prout","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0150","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non\u2013muscle-invasive bladder cancer\u2014a randomised controlled trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.08.001_b0165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non\u2013muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0170","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.08.001_b0175","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","article-title":"Chemoablation with intensive intravesical mitomycin C treatment: a new approach for non\u2013muscle-invasive bladder cancer","volume":"2","author":"Racioppi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.08.001_b0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/annonc\/mdi124","article-title":"Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients","volume":"16","author":"Moskovitz","year":"2005","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.euo.2024.08.001_b0190","first-page":"e368","article-title":"PD19-10 The chemoablative effect of Vesigel instillation in patients with NMIBC \u2013 response rate and 1-year durability","volume":"197","author":"Lenis","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0200","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2024.08.001_b0205","first-page":"e627","article-title":"PD30-09 Response to primary chemoablation with UGN-102 in patients with new or recurrent LG IR NMIBC: post-hoc analysis of the Atlas trial","volume":"211","author":"Prasad","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American Urological Association\u2013defined intermediate-risk non\u2013muscle-invasive bladder cancer patients: a phase 1b study","volume":"62","author":"van Valenberg","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.08.001_b0215","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.08.001_b0220","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/JU.0000000000002941","article-title":"Patient and provider perception of transurethral resection of bladder tumor vs chemoablation for nonmuscle-invasive bladder cancer treatment","volume":"209","author":"Parisse","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0225","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00345-014-1337-y","article-title":"Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014","volume":"33","author":"Kramer","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2022.08.012","volume":"83","author":"Pedersen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euf.2021.01.019","article-title":"A systematic review of the efficacy and safety of outpatient bladder tumour ablation","volume":"8","author":"Malde","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.08.001_b0240","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1089\/end.2013.0241","article-title":"An analysis of the efficacy, safety, and cost-effectiveness of fulguration under local anesthesia for small-sized recurrent masses: a comparative analysis to transurethral resection of bladder tumors in a matched cohort","volume":"27","author":"Park","year":"2013","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2024.08.001_b0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bju.16269","article-title":"Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer","volume":"133","author":"Vitug","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.08.001_b0250","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/21681805.2018.1450782","article-title":"Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation: efficacy, safety and economic analysis","volume":"52","author":"Hermann","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0255","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.urology.2014.09.041","article-title":"A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration","volume":"85","author":"Al Hussein Al Awamlh","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.08.001_b0260","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0022-5347(17)39742-2","article-title":"Outpatient flexible cystoscopy and fulguration of recurrent superficial bladder tumors","volume":"144","author":"Herr","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0265","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.ju.0000103100.22951.5e","article-title":"Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm","volume":"171","author":"Donat","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.08.001_b0270","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1089\/end.2019.0253","article-title":"Long-term prospective outcomes of patients with non-muscle invasive bladder cancer after holmium laser ablation","volume":"33","author":"Darrad","year":"2019","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2024.08.001_b0275","doi-asserted-by":"crossref","unstructured":"Soria F, Rosazza M, Livoti S, et al. Clinical validation of the intermediate-risk non\u2013muscle-invasive bladder cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a multicenter Young Academic Urologists Urothelial Working Group Collaboration. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.06.004.","DOI":"10.1016\/j.euo.2024.06.004"},{"key":"10.1016\/j.euo.2024.08.001_b0280","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2017.08.007","article-title":"Predicting grade and stage at cystoscopy in newly presenting bladder cancers\u2014a prospective double-blind clinical study","volume":"109","author":"Mariappan","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.08.001_b0285","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112400186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112400186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T21:42:55Z","timestamp":1739223775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112400186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S258893112400186X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.08.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG)","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}